
Prilenia and Ferrer Share European Regulatory Update on Pridopidine for Huntington’s Disease
Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorization for pridopidine’s marketing authorization…












